WebAbout us. Biotheus (普米斯生物技术) aims to discover and develop effective therapeutic biologics for patients with cancer and inflammatory disease. We believe in creative … WebBiotheus. Private Company. Founded 2024. China. Founded in April 2024, we are a biotech startup focusing on the discovery and development of next generation antibody-based therapeutics. Our HQ is located in Zhuhai, China, with R&D capabilities including antibody discovery, process development and analytical assessment platforms, including a ...
TILT Biotherapeutics Signs a Licensing Deal with Biotheus, Inc …
WebBiotheus Inc. was granted an IND in March 2024 for its bispecific therapeutic asset, PM8001. Regulatory approval was attained with help from the Solentim VIPS™ system for single cell cloning and clonality reporting. In this article, Dr Andy Tsun, Co-Founder and VP of Discovery Biology at Biotheus Inc, shares his WebMar 7, 2024 · PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This is a phase II/III study to evaluate the efficacy and safety of PM8002 in combination with pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic non-squamous NSCLC who have failed to EGFR-TKI treatment. Detailed Description: script slap battle
Similar companies to Wellstat Ophthalmics VentureRadar
WebNov 7, 2024 · MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a collaboration with Biotheus, a China-based biotech company focused on developing treatments for cancer and autoimmune diseases. WebBiotheus is an up-and-coming biotech company focused on curing malignant tumors and autoimmune diseases. Biotheus is committed to research and development, and commercialization of first-class … WebJan 27, 2024 · HELSINKI-- ( BUSINESS WIRE )-- TILT Biotherapeutics (“TILT”), a privately held biopharmaceutical company based in Helsinki, Finland, today announces that they have signed a license agreement with... script slap battles👏